Henao-Mejia and colleagues have demonstrated that the NLRP6 and NLRP3 inflammasomes and their effector IL-18 can negatively regulate NAFLD/NASH progression as well as multiple aspects of metabolic syndrome by modulating the gut microbiota [168]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.